The weekly litigation news digest is live. Subscribe now
Method For Preventing Or Treating Osteoporosis Characterized By Administering Teriparatide Or Salt Thereof Twice A Week - EP3875105
The patent EP3875105 was granted to Asahi Kasei Pharma on Nov 27, 2024. The application was originally filed on Jul 31, 2019 under application number EP19879778A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3875105
- Application Number
- EP19879778A
- Filing Date
- Jul 31, 2019
- Status
- Granted And Under Opposition
- Oct 25, 2024
- Publication Date
- Nov 27, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Teriparatide or a salt thereof for preventing or treating osteoporosis in a human patient, characterized by administration of a 28.2 µg unit dose at a frequency of twice a week, with intervals of 2 and 3 days between administrations.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (5) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents